PMK N02RS1

Drug Profile

PMK N02RS1

Alternative Names: N-02RS1; PMK-N02RS1

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PharmaKing
  • Class Antibronchitics; Herbal medicines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchitis

Most Recent Events

  • 06 Apr 2017 Phase-II development for chronic low-grade respiratory diseases, specifically Bronchitis, is ongoing in South Korea (PO)
  • 01 Mar 2016 PharmaKing completes a phase IIb trial for Bronchitis in South Korea (PO) (NCT02637310)
  • 01 Dec 2015 PharmaKing initiates a phase IIb trial for Bronchitis in South Korea (PO) (NCT02637310)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top